Search company, investor...

Natus Medical

Founded Year



Acq - P2P | Acquired

Total Raised




About Natus Medical

Natus is a provider of healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. The company was founded in 1987 and is based in Pleasanton, CA. In July 2022, Natus Medical was acquired by ArchiMed.2B.

Headquarters Location

6701 Koll Center Parkway Suite 120

Pleasanton, California, 94566,

United States


Missing: Natus Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Natus Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Natus Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Natus Medical is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Natus Medical Patents

Natus Medical has filed 32 patents.

The 3 most popular patent topics include:

  • Microscopy
  • Vision
  • Audiology
patents chart

Application Date

Grant Date


Related Topics




Ophthalmology, Vision, Diseases of the eye and adnexa, Microscopy, Optical devices


Application Date


Grant Date



Related Topics

Ophthalmology, Vision, Diseases of the eye and adnexa, Microscopy, Optical devices



Latest Natus Medical News

Neurotechnology Global Market Report 2023

Jun 1, 2023

" - , Natus Medical Incorporated, Abbott, Boston Scientific Corporation, Cleveland Medical Devices Inc., Cogentix Medical Inc., Nihon Kohden Corporation and LivaNova PLC. The global neurotechnology market is expected to grow from $11.90 billion in 2022 to $13.44 billion in 2023 at a compound annual growth rate (CAGR) of 12.89%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neurotechnology market is expected to reach $21.97 billion in 2027 at a CAGR of 13.07%. The neurotechnology market includes revenues earned by entities from neuro-rehabilitative treatment, heart rate variability, electroencephalography, and neurostimulation.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.The neurotechnology market consists of sales of brain-computer interfaces (BCIs), neurostimulation devices, virtual reality (VR), and prosthetic limb devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. Neurotechnology is the study and interaction of the nervous system, which includes the brain and other parts of the nervous system. Neurotechnology can be used in clinical settings to influence the brain or nervous system, such as in therapeutic or rehabilitative contexts. North America was the largest region in the neurotechnology market in 2022.Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The main neurotechnology conditions are cognitive disorders, pain treatment, urinary and faecal incontinence, epilepsy, parkinson’s disease, hearing conditions, sleep disorder, depression, and others.Cognitive disorders refer to a significant decline in an individual’s cognitive function, to an extent that without treatment, it becomes challenging to perform regular social activities. The various types are imaging modalities, neurostimulation, cranial surface measurement, neurological implants, and others used by ambulatory surgical centres, hospitals, homecare facilities, and others. The increased prevalence of neurological conditions is expected to propel the growth of the neurotechnology market going forward.A neurological condition is any disorder or disease that affects the brain; common neurological conditions include Alzheimer’s disease, Parkinson’s disease, epilepsy, and migraine. Neurotechnology is being used to diagnose and treat neurological disorders in a variety of ways, including brain imaging, neurostimulation, neurofeedback, and brain-computer interfaces. For instance, in January 2022, according to the American Heart Association Inc., a US-based non-profit organization, Alzheimer’s disease, and related dementias were expected to affect 9.3 million people in the United States by 2060. Additionally, in February 2023, according to the World Health Organisation (WHO), a Switzerland-based intergovernmental organization, an estimated 5 million people worldwide will be diagnosed with epilepsy every year. Therefore, the increased prevalence of neurological conditions is driving the growth of the neurotechnology market going forward. Technological advancements are a key trend gaining popularity in the neurotechnology market.Companies operating in the neurotechnology market are adopting new technologies to sustain their position in the market. For instance, in November 2022, Blackrock Neurotech, a US-based biotechnology company, launched Neuralace, a next-generation technology for neurotechnology.Neuralace looks like a piece of lace thinner than an eyelash, and it can cover large areas of the brain’s surface. The Neuralace platform was designed as an ultra-high channel count, flexible electrode that provides a glimpse into the technology that will power its future BCIs. The system assisted patients in regaining tactile function, limb and prosthetic movement, and the ability to control digital devices. In April 2022, Blackrock Neurotech, a US-based biotechnology company, acquired Mindx Corporation for an undisclosed sum.Through this deal, Blackrock’s software portfolio is set to expand with its latest acquisition, paving the way for the company to provide integrated BCI products with cutting-edge features. This move positions Blackrock to offer a full-stack solution to its customers. Mindx Corporation is a US-based creator of a neuron technology framework for use in spatial computing applications. The countries covered in the neurotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The neurotechnology market research report is one of a series of new reports that provides neurotechnology market statistics, including neurotechnology industry global market size, regional shares, competitors with a neurotechnology market share, detailed neurotechnology market segments, market trends and opportunities, and any further data you may need to thrive in the neurotechnology industry. This neurotechnology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Natus Medical Frequently Asked Questions (FAQ)

  • When was Natus Medical founded?

    Natus Medical was founded in 1987.

  • Where is Natus Medical's headquarters?

    Natus Medical's headquarters is located at 6701 Koll Center Parkway, Pleasanton.

  • What is Natus Medical's latest funding round?

    Natus Medical's latest funding round is Acq - P2P.

  • How much did Natus Medical raise?

    Natus Medical raised a total of $6.35M.

  • Who are the investors of Natus Medical?

    Investors of Natus Medical include ArchiMed, Trinity Ventures and Aurora Funds.

  • Who are Natus Medical's competitors?

    Competitors of Natus Medical include AngelEye Health, M2S, Micronics Microfluidics, EraGen Biosciences, Molecular Detection and 12 more.

Compare Natus Medical to Competitors


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

Binx Health Logo
Binx Health

Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.

BrainScope Logo

BrainScope develops technology that aims to enable physicians to evaluate neurological function in trauma cases as well as to diagnose medical conditions that impact brain status.

Atonomics Logo

Atonomics develops a point of care diagnostic device based on an electro-mechanical concept. This technology changes the way that DNA and antibodies are used in point of care diagnosis.


NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

Forth Photonics

Forth Photonics is a medical device company that designs, develops, manufactures and markets imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. Forth Photonics aims to help medical practitioners to improve patient care by incorporating advanced biophotonics and optical molecular imaging technologies to assist in early detection, diagnosis and monitoring.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.